Skip to content
ClinCalc Pro
Menu
Thyroid hormone (T3)

Liothyronine sodium (T3)

Brand names: Cytomel, Tertroxin

The synthetic form of the active thyroid hormone tri-iodothyronine (T3), used for severe or acute hypothyroid states such as myxoedema coma and occasionally as an adjunct in selected patients, where its rapid onset is advantageous over levothyroxine.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Liothyronine is the biologically active thyroid hormone that binds nuclear thyroid receptors to regulate metabolism, but unlike levothyroxine it acts directly without requiring peripheral conversion.

Prescribing in practice

  • Its rapid, potent action makes cardiac adverse effects more likely, so start at a low dose and titrate cautiously, especially in the elderly and in those with ischaemic heart disease.
  • It has a shorter half-life than levothyroxine, giving a faster onset and offset but more fluctuation in hormone levels.
  • Routine substitution of liothyronine for levothyroxine in primary hypothyroidism is not recommended and should be a specialist decision.

Monitoring

Monitor thyroid function and clinical response, together with heart rate and any cardiac symptoms during dose titration.

Counselling the patient

  • Take exactly as prescribed and do not change the dose yourself.
  • Report palpitations, chest pain, tremor or marked anxiety.
  • This is a specialist-initiated treatment and needs regular blood-test review.

Evidence & guidelines

Liothyronine has a defined role in myxoedema coma and specialist scenarios; routine combination or substitution therapy is not supported by NICE/endocrine guidance for most patients with primary hypothyroidism.

Reference: BTA position statement; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.